China Resources Double-Crane Pharmaceutical Stock Forecast for 2023 - 2025 - 2030
Updated on 04/25/2024
China Resources Double-Crane Pharmaceutical Stock Forecast and Price Target
The average target price for China Resources Double-Crane Pharmaceutical's stock set by renowned analysts in recent months is ¥25.74, representing a potential upside of approximately 21.59% from its last closing price if met by 2025. This estimation is based on a high estimate of ¥26.00 and a low estimate of ¥23.00. If you are interested in 600062 stock, it is important to also consider its competitors.
21.59% Upside
China Resources Double-Crane Pharmaceutical Fair Value Forecast for 2023 - 2025 - 2030
China Resources Double-Crane Pharmaceutical's Price has decreased In the last year, from ¥9.36 to ¥0.00 – a 100.00% drop. For next year, analysts predict Fair Value of ¥15.87, which would mean an increase of 100.00%. Over the next seven years, experts predict that China Resources Double-Crane Pharmaceutical's Fair Value will grow at a rate of 100.00%.
China Resources Double-Crane Pharmaceutical Revenue Forecast for 2023 - 2025 - 2030
In the last two years, China Resources Double-Crane Pharmaceutical's Revenue has grown by 11.09%, rising from ¥8.50B to ¥9.45B. For next year, analysts predict Revenue of ¥12.08B, which would mean an increase of 27.83%. Over the next seven years, experts predict that China Resources Double-Crane Pharmaceutical's Revenue will grow at a rate of 32.45%.
.jpg)
China Resources Double-Crane Pharmaceutical Dividend per Share Forecast for 2023 - 2025 - 2030
In the last two years, China Resources Double-Crane Pharmaceutical's Dividend per Share has grown by 100.00%, rising from ¥0.29 to ¥0.58. For next year, analysts predict Dividend per Share of ¥0.77, which would mean an increase of 32.76%. Over the next seven years, experts predict that China Resources Double-Crane Pharmaceutical's Dividend per Share will grow at a rate of 31.27%.
China Resources Double-Crane Pharmaceutical EBITDA Forecast for 2023 - 2025 - 2030
China Resources Double-Crane Pharmaceutical's EBITDA has grown In the last two years, rising from ¥1.54B to ¥1.73B – a growth of 12.29%. In the next year, analysts believe that EBITDA will reach ¥2.26B – an increase of 30.40%. For the next seven years, experts predict that China Resources Double-Crane Pharmaceutical's EBITDA will grow at a rate of 45.25%.
China Resources Double-Crane Pharmaceutical EBIT Forecast for 2023 - 2025 - 2030
China Resources Double-Crane Pharmaceutical's EBIT has seen impressive growth In the last two years, rising from ¥1.17B to ¥1.22B – a growth of 3.76%. In the next year, analysts believe that EBIT will reach ¥1.91B – an increase of 56.49%. For the next seven years, the forecast is for EBIT to grow by 70.33%.
China Resources Double-Crane Pharmaceutical EPS Price Prediction Forecast for 2023 - 2025 - 2030
China Resources Double-Crane Pharmaceutical's EPS has decreased In the last year, from ¥0.92 to ¥0.00 – a 100.00% drop. For next year, analysts predict EPS of ¥1.56, which would mean an increase of 100.00%. Over the next seven years, experts predict that China Resources Double-Crane Pharmaceutical's EPS will grow at a rate of 100.00%.
Site Navigation
.jpg)